Novavax says protein vaccine works for kids as young as 12

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12

Novavax announced Thursday that its COVID-19 vaccine proved safe and effective in a study of 12- to 17-year-olds.

Novavax makes a protein-based vaccine -- a different type than the most widely used shots -- that’s a late arrival to the COVID-19 arsenal.

Its shots have been cleared for use in adults by regulators in Britain, Europe and elsewhere and by the World Health Organization, and are under review by the U.S. Food and Drug Administration.

Armed with the new data, Novavax plans to soon seek expanded use of its shots down to age 12. Later this year, it plans to begin testing in younger children.